Search research articles
Contact Us
Filters
Showing results (51-60 of 60) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 60 results.
European Journal of Nuclear Medicine and Molecular Imaging
|
May 15, 2020
Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer
Stefan A Koerber, Katharina Sprute, Clemens Kratochwil, et al.
International Journal of Cancer
|
April 20, 2026
Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II Trial
Benedikt Niedermaier, Tilmann Bochtler, Florian Eichhorn, et al.
Leukemia
|
May 19, 2021
JunB is a key regulator of multiple myeloma bone marrow angiogenesis
Fengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2016
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Tomasz M Beer, Eugene D Kwon, Charles G Drake, et al.
Nature Medicine
|
May 31, 2026
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
Martin Wermke, Sebastian Ochsenreither, Dirk Jaeger, et al.
Cancer Cell
|
April 13, 2016
Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients
Niels Halama, Inka Zoernig, Anna Berthel, et al.
Molecular Cancer
|
January 10, 2024
Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold
Tim Schmäche, Juliane Fohgrub, Anna Klimova, et al.
Cell Research
|
January 14, 2015
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
Dalil Hannani, Marie Vétizou, David Enot, et al.
Nature Genetics
|
June 20, 2018
A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors
Mariano J Alvarez, Prem S Subramaniam, Laura H Tang, et al.
Nature Medicine
|
January 6, 2025
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
Juanita Lopez, Thomas Powles, Fadi Braiteh, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 60) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 60 results.
European Journal of Nuclear Medicine and Molecular Imaging
|
May 15, 2020
Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer
Stefan A Koerber, Katharina Sprute, Clemens Kratochwil, et al.
International Journal of Cancer
|
April 20, 2026
Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II Trial
Benedikt Niedermaier, Tilmann Bochtler, Florian Eichhorn, et al.
Leukemia
|
May 19, 2021
JunB is a key regulator of multiple myeloma bone marrow angiogenesis
Fengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2016
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Tomasz M Beer, Eugene D Kwon, Charles G Drake, et al.
Nature Medicine
|
May 31, 2026
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
Martin Wermke, Sebastian Ochsenreither, Dirk Jaeger, et al.
Cancer Cell
|
April 13, 2016
Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients
Niels Halama, Inka Zoernig, Anna Berthel, et al.
Molecular Cancer
|
January 10, 2024
Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold
Tim Schmäche, Juliane Fohgrub, Anna Klimova, et al.
Cell Research
|
January 14, 2015
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
Dalil Hannani, Marie Vétizou, David Enot, et al.
Nature Genetics
|
June 20, 2018
A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors
Mariano J Alvarez, Prem S Subramaniam, Laura H Tang, et al.
Nature Medicine
|
January 6, 2025
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
Juanita Lopez, Thomas Powles, Fadi Braiteh, et al.
Page
of 6